3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
31
INDUSTRY
21
NIH
8
FED
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Classical hematology
1
Conditions
Prostatic Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Fanconi Anemia, Complementation Group N
1
Fanconi Anemia, Complementation Group D1
1
Interventions
enzalutamide
4
pembrolizumab
3
apalutamide
3
Docetaxel
3
Abiraterone Acetate
3
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
3
abiraterone
2
Testosterone
2
Prednisone
2
Leuprolide
2
Cholecalciferol
2
Celecoxib
2
Androgen Antagonists
2
sulforaphane
1
relugolix
1
olaparib
1
nilutamide
1
histrelin
1
gallium 68 PSMA-11
1
copanlisib
1
capivasertib
1
bicalutamide
1
avelumab
1
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
1
Yoga
1
Triptorelin Pamoate
1
Tablets
1
Simvastatin
1
Sildenafil Citrate
1
Radiosurgery
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
FED
×
olaparib
×
Genitourinary
×
Clear all
NCT04038502
2025-08-20
COBRA
VA Office of Research and Development
Phase 2
Recruiting
100 enrolled